Liraglutide and Cardio-Metabolic Risk Markers
This trial is active, not recruiting.
|Sponsor||University of Palermo|
|Start date||June 2012|
|End date||December 2015|
|Trial size||300 participants|
|Trial identifier||NCT01715428, LIRAGLUTIDE UNIPA|
Incretin-based therapies have shown significant effects beyond those on glucose metabolism. We aim in the present study to evaluate the effects of liraglutide on several cardio-metabolic risk markers.
administration of liraglutide at 1.2 mg/daily
carotid intima-media thickness
time frame: every four months for a total period of 2 years
changes in oxidative stress, ghrelin, atherogenic lipoproteins, heat shock proteins
time frame: after 2 months of therapy
Male or female participants from 18 years up to 80 years old.
Inclusion Criteria: - patients with a diagnosis of type-2 diabetes Exclusion Criteria: - severe hepatic or renal diseases
|Official title||Effects of Liraglutide on Cardio-Metabolic Risk Markers|
|Description||In details, we will evaluate the effects of liraglutide on carotid-intima media thickness, oxidative stress, ghrelin, heat shock proteins and lipoproteins.|
Call for more information